Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (11969)	12/2/1997 10:55:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

FUGAZI, Although LGND will be receiving a significant amount of up front cash from LLY, they are still grossly underfunded and can't do everything as quickly as they would like. As far as I know, the only Asian trials are in Japan by Sankyo for Galardin. LGND did have a European and Australian presence from the International Panretin trials, as well as the type II diabetes trial, but your list looks like an expansion in Europe (I don't remember seeing Poland or Spain listed previously or as many sites in France).